Tracking fatty liver disease progression in Chinese patients
Part of Digestive system clinical trials.
This study tracks the progression of fatty liver disease and NASH in Chinese patients. It aims to better understand how the condition develops over time, which may help improve future treatments and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 6 years old or older.
- You must have a diagnosis of fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
- You must not drink more than 21 alcoholic drinks per week (men) or 14 drinks per week (women).
- You cannot have other liver diseases such as hepatitis B, hepatitis C, autoimmune liver disease, or Wilson's disease.
- You cannot be enrolled in any other NASH-related clinical trial currently.
- You cannot have had weight-loss surgery within the last year, and you cannot be planning to have it during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a long-term study that follows adults who are being managed for fatty liver (NAFL) or NASH to learn how these conditions change over time. It may help researchers better understand what to expect and how care decisions could be improved.
This study follows adults with fatty liver to learn more about how it progresses and what patterns are common. It may help improve future ways of identifying and monitoring fatty liver.
This trial looks at nonalcoholic steatohepatitis (fatty liver with inflammation) in children. It is meant to test whether a new approach can help improve this liver problem without being caused by alcohol or other known liver diseases.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
This study tracks how liver scarring (fibrosis) and fat buildup (steatosis) change over time in people with nonalcoholic fatty liver disease (NAFLD). It helps doctors understand risk factors so they can better predict and manage the disease.
This study collects health information and samples from people with non-alcoholic fatty liver disease to better understand the condition. It may help researchers find new ways to diagnose or treat this liver problem.
Hear when a new NASH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.